• head_banner_01

Manufacturing Companies for Cas 319460-85-0 - Semaglutide for Type 2 Diabetes – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We take "customer-friendly, quality-oriented, integrative, innovative" as objectives. "Truth and honesty" is our administration ideal for Coenzyme Q10, Chloride 104, 1-Carbethoxy-4-Piperidone, We're searching ahead to setting up long-term company associations with you. Your comments and solutions are remarkably appreciated.
Manufacturing Companies for Cas 319460-85-0 - Semaglutide for Type 2 Diabetes – Gentolex Detail:

Product Detail

Name  Semaglutide
CAS number  910463-68-2
Molecular formula  C187H291N45O59
Molecular weight  4113.57754
EINECS Number  203-405-2

Synonyms

Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic, 

Description

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs, and semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA).

Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Application

Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.

Bioactivity

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of GLP-1receptor, with a potential type 2 Therapeutic efficacy of diabetes mellitus (T2DM).

Quality System

In general, quality system and assurance is in place covering all stage of production of the finished product. Adequate manufacturing and control operations are performed in compliance with the approved procedures/ specifications. Change control and Deviation handling system is in place, and necessary impact assessment and investigation were conducted. Proper procedures are in place to ensure quality of product prior to release into the market.


Product detail pictures:

Manufacturing Companies for Cas 319460-85-0 - Semaglutide for Type 2 Diabetes – Gentolex detail pictures

Manufacturing Companies for Cas 319460-85-0 - Semaglutide for Type 2 Diabetes – Gentolex detail pictures


Related Product Guide:

It adheres for the tenet "Honest, industrious, enterprising, innovative" to develop new products and solutions continuously. It regards shoppers, success as its individual success. Let us produce prosperous future hand in hand for Manufacturing Companies for Cas 319460-85-0 - Semaglutide for Type 2 Diabetes – Gentolex , The product will supply to all over the world, such as: Tunisia, Vietnam, Nigeria, Company name, is always regarding quality as company' s foundation, seeking for development via high degree of credibility , abiding by ISO quality management standard strictly, creating top-ranking company by spirit of progress-marking honesty and optimism.
  • In our cooperated wholesalers, this company has the best quality and reasonable price, they are our first choice.
    5 Stars By Norma from Mauritania - 2017.06.25 12:48
    This company has the idea of "better quality, lower processing costs, prices are more reasonable", so they have competitive product quality and price, that's the main reason we chose to cooperate.
    5 Stars By Catherine from Rio de Janeiro - 2018.12.30 10:21
    Write your message here and send it to us